Real-world insights into safety, tolerability, and predictive factors of adverse drug reactions in treating idiopathic pulmonary fibrosis with pirfenidone and nintedanib

Real-world insights into safety, tolerability, and predictive factors of adverse drug reactions in treating idiopathic pulmonary fibrosis with pirfenidone and nintedanib

Background: Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, life-threatening lung disease with a global incidence of 0.09–1.30 per 10,000 individuals. Pirfenidone and nintedanib are the approved treatments for IPF. Objectives: This study evaluated the real-world safety and tolerabilit...

Full description

Saved in:
Bibliographic Details
Main Authors: Alessio Provenzani, Daniele Leonardi Vinci, Miriam Alaimo, Salvatore Di Maria, Fabio Tuzzolino, Gaetano Floridia, Roberta Di Stefano, Anna Carollo, Adriana Callari, Piera Polidori, Patrizio Vitulo
Format: Article
Language:English
Published: SAGE Publishing 2025-05-01
Series:Therapeutic Advances in Drug Safety
Online Access:https://doi.org/10.1177/20420986251341645
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items